CTOs on the Move

Southern Veterinary Partners

www.svp.vet

 
Southern Veterinary Partners is a network of animal hospitals in the South that provides high quality veterinary care to companion animals with exceptional client experiences.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.svp.vet
  • 2204, Lakeshore Drive
    Birmingham, AL USA 35209
  • Phone: 205.453.4761

Executives

Name Title Contact Details

Similar Companies

Convergence Ct

Convergence Ct is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chuze Fitness

Chuze Fitness is a local gym featuring low prices and state of the art facilities & equipment. We welcome individuals of all fitness levels. Visit today!

Complete Healthcare Communications Inc

Complete Healthcare Communications Inc is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Demant

Demant A/S is a leading international hearing health care company within hearing aids, audiometric equipment, and personal communication.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.